AstraZeneca / Alexion Pharmaceuticals merger inquiry

The CMA investigated and cleared the anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc.

Statutory timetable

Phase 1 date Action
14 July 2021 Decision announced
21 July 2021 Deadline for phase 1 decision
25 May 2021 to 3 June 2021 Invitation to comment
25 May 2021 Launch of merger inquiry

Phase 1

CMA clearance decision

14 July 2021: The CMA has cleared the anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc.

Launch of merger inquiry

25 May 2021: The CMA announced the launch of its merger inquiry by notice to the parties.

Invitation to comment: closed 3 June 2021

25 May 2021: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

To assist it with this assessment, the CMA invites comments on the transaction from any interested party.

These comments should be provided by the deadline set out above.

Contact

Please send written representations about any competition issues to:

general.enquiries@cma.gov.uk

Updates to this page

Published 25 May 2021
Last updated 18 August 2021 + show all updates
  1. Full text decision published.

  2. Clearance decision announced.

  3. First published.